Reccurent vulvovaginal candidiasis in a patient with systemic lupus erythematosus: A case report
DOI:
https://doi.org/10.66344/jpad.v33i2.2100Abstract
A 30-years-old woman complaint of intermittent itchy yellowish vaginal discharge since 1 year ago. The patient has SLE since 6 years ago. Inspeculo examination showed vaginal and cervical erythema accompanied by yellowish white, cheese-like discharge. Direct microscopic examination using 10% KOH showed budding yeast cells and pseudohyphae. Culture examination showed C. glabrata and resistance to fluconazole. The patient was treated with intravaginal nystatin 100.000 iu for 14 days followed by 100.000 iµ for 14 days every month. Clinical improvement was found in two months after treatment.
References
1. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016; 214(1):2-21.
2. Blostein F, Levin-Sparenberg E, Wagner J, et al. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27(9):1-35.
3. Riel SJ, Lardenoije CMJG, Oudhuis GJ, et al. Treating (recurrent) vulvovaginal candidiasis with medical-grade honey- concepts and practical considerations. J Fungi. 2021;7(664):1-18.
4. Akimoto-gunther L, Bonfim-mendonça PDS, Takahachi G. Factors to recurrent vulvovaginal candidiasis: Chronic stress and reduced antioxidant capacity. PLoS One. 2016;11(7):1-14.
5. Farr A, Effendy I, Tirri B, et al. Guideline: Vulvovaginal candidosis. Mycosis Diagnosis, Ther Prophyl Fungal Dis. 2021; 64(6):1-20.
6. Farhan MA, Moharram AM, Salah T, et al. Types of yeasts that cause vulvovaginal candidiasis in chronic users of corticosteroids. Med Mycol. 2019;57(6):1-7.
7. Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans candida species in vulvovaginitis. J Fungi. 2018;4(4):1-17.
8. Saxon C, Edwards A, Rautemaa-Richardson R, et al. British association for sexual dealth and HIV national guideline for the management of vulvovaginal candidiasis. Int J STD AIDS. 2020;31(12):1124-44.
9. Talaei Z, Sheikhbahaei S, Ostadi V, et al. Recurrent vulvovaginal candidiasis: Could it be related to cell-mediated immunity defect in response to Candida antigen? Int J Fertil Steril. 2017;11(3):134-41.
10. Yassin MT, Mostafa AA, Al-Askar AA, et al. In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis. Eur J Med Res. 2020;25(1):1-9.
11. Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection. Expert Rev Clin Immunol. 2020;16(5):1-13.
12. Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine and cyclophosphamide in nonmalignant hematologic diseases. Hematol (United States). 2020;20(1):319-27.
13. Selimoğlu MA, Kaya S, Güngör Ş, et al. Infection risk after paediatric liver transplantation. Turk J Pediatr. 2020;62(1):46-52.
14. Zhang JY, Liu JH, Liu F Di, et al. Vulvovaginal candidiasis: Species distribution, fluconazole resistance and drug efflux pump gene overexpression. Mycoses. 2014;57(10):584-51.
15. Chew SY, Than LTL. Vulvovaginal candidosis: Contemporary challenges and the future of prophylactic and therapeutic approaches. Mycoses. 2016;59(5):262-73.
16. Sedigheh Hosseini S, Joshaghani H, Shokohi T, et al. Antifungal activity of ZnO nanoparticles and nystatin and downregulation of SAP1-3 genes expression in fluconazole-resistant candida albicans isolates from vulvovaginal candidiasis. Infect Drug Resist. 2020;13(2):385-94.
17. Jeyachandran Manohari P, Cs V, Ps M, Janakiraman K. Formulation and evaluation of nystatin vaginal tablet. Pelagia Res Libr. 2017;8(1):1-10.
18. Khalandi H, Masoori L, Farahyar S, et al. Antifungal activity of capric acid, nystatin, and fluconazole and their in vitro interactions against candida isolates from neonatal oral thrush. Assay Drug Dev Technol. 2020;18(4):195-201.
19. Fan S, Liu X, Wu C, et al. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia. 2015;179(1-2):95-101.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Annisa Marsha Evanti, E Nurfaiqoh, AW Pramudita, EY Ellistasari
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
